CA
NZ
UK
AU
IND
US
Spero Therapeutics (NASDAQ: SPRO) is a clinical‑stage biotechnology company valued at $71 million that disclosed a cash balance of $50.8 million as of June 30 2026. This figure excludes the proceeds from a royalty‑backed financing that closed in July 2026, a transaction the firm …
The earnings per share of $0.02 exceeded the consensus estimate of $-0.27, signaling strong competitive positioning.
QT Imaging Holdings, Inc. reported second‑quarter revenue of $7.4 million, representing a 103 % increase over the $3.7 million recorded a year earlier. The surge was driven by the shipment of fifteen Breast Acoustic CT scanners during the quarter, adding to a cumulative total …
With shares currently down 32.7% year-to-date, the financial outlook raises concerns about the broader implications for investor sentiment and market confidence in Sera Prognostics. This performance positions the company in a challenging environment as it seeks to stabilize its financial footing.
STAAR Surgical Co. (NASDAQ: STAA), a leading provider in the medical specialties industry, reported an exceptional second quarter performance, achieving net sales of $93.5 million, which represents a stunning 111% increase compared to the previous year. This surge in revenue showcases the effectiveness of …
Its focus on thyroid products has yielded promising operational results and shows potential for sustained growth.
This result marked a slight miss against the consensus estimate of $-0.18 per share. The company's marketCapitalizationstands at approximately $24 million, while it recorded revenue of $1.20 million during the last twelve months, a stark 45.3% decline year-over-year.
The complexities surrounding Medicaid's estate recovery process have intensified as families grapple with the death of loved ones. Families find that Medicaid can lay claims to the estates of deceased beneficiaries, putting significant financial pressure on them. This policy can threaten the family home …
Novo Nordisk has launched a legal challenge against Eli Lilly over allegations regarding misleading advertising of its weight-loss medication. The lawsuit highlights concerns within the pharmaceutical sector regarding ethical advertising practices and competitive fairness. Novo Nordisk's CEO defended the decision to sue, stating that …
Omeros Corp (NASDAQ: OMER) entered the market on August 12 with a $992 million market capitalisation, bolstered by $132 million in cash and short‑term investments and offset by $73.29 million of reported debt. The company’s YARTEMLEA® franchise produced $32.2 million in gross revenue this …
Please wait processing your request...